|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Rating Action: Moody's to withdraw Alere's ratings following debt redemption. Global Credit Research- 05 Oct 2017. New York, October 05, 2017-- Moody's Investors Service will withdraw Alere Inc.' s ratings ...
NEW YORK , Oct. 3, 2017 /PRNewswire/ -- Alere Inc. (ALR) Lifshitz & Miller announces that on August 23, 2017 , the U.S. District Court for the District of Massachusetts denied ALR's motion to dismiss a ...
Alere's acquisition would help Abbott (ABT) explore new channels and geographies, including forays into fast growing outlets like doctors' offices, clinics, pharmacies and at-home testing.
The Federal Trade Commission recently announced the US antitrust approval for Abbott Laboratories' (ABT) acquisition of Alere (ALR).
Short interest is low for ALR with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding ALR are favorable, with net inflows of $2.40 billion.
LONDON, UK / ACCESSWIRE / October 2, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Alere Inc. (NYSE: ALR ), following which we have published a free ...
WALTHAM, Mass., Oct. 2, 2017 /PRNewswire/ -- Alere Inc. (ALR), a global leader in rapid diagnostics, today announced that its Alere™ i Influenza A & B 2 test has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for the detection of influenza A and B infection in children and adults. Alere i Influenza A & B 2 is a second-generation rapid molecular assay, which delivers lab accurate results in less time, with the ability to report a positive result in as little as 5 minutes. Alere i Influenza A & B 2 also offers increased sample flexibility with nasopharyngeal swabs now validated for direct use, as well as, in transport media.
WALTHAM, Mass. , Sept. 29, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company"), a global leader in rapid diagnostic tests, today announced the U.S. Department of Justice (the "DOJ") ...
WALTHAM, Mass., Sept. 29, 2017 /PRNewswire/ -- Alere Inc. (ALR) announced today that Abbott's acquisition of Alere is intended to close on October 3, 2017. Alere intends to request that the New York Stock Exchange cease trading of Alere's common stock before market open on October 3, 2017. Alere believes that when diagnosing and monitoring health conditions, Knowing now matters™.
WALTHAM, Mass., Sept. 28, 2017 /PRNewswire/ -- Alere Inc. (ALR) (the "Company"), a global leader in rapid diagnostic tests, today announced that it has reached an agreement in principle to settle with the U.S. Department of Justice (the "DOJ") to resolve various potential civil claims, including claims under the False Claims Act, relating to Alere Triage® cardiac and Toxicology products sold between January 2006 and March 31, 2012. The settlement relates to matters arising out of the previously disclosed 2012 FDA inspection of Alere San Diego and the Office of Inspector General subpoena.
Abbott Laboratories has won U.S. antitrust approval to buy Alere Inc on condition that it sell two point-of-care medical testing businesses, the Federal Trade Commission said on Thursday. Alere's shares were up 3.5 percent at $50.61 in mid-afternoon trading on Thursday while Abbott was up 3 percent at $53.72. Abbott first offered to buy Alere in February 2016, but the deal ran into trouble because of issues related to the diagnostic maker's accounting and sales practices.
Alere Inc has agreed to pay more than $13 million to resolve charges the diagnostic testing firm committed accounting fraud and made improper payments to foreign officials, the U.S. Securities and Exchange Commission said on Thursday. The settlement with Alere resolved an investigation that began in 2015 before Abbott Laboratories agreed to buy the Waltham, Massachusetts-based company in a $5.3 billion deal expected to close later this year.
WALTHAM, Mass. , Sept. 28, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company"), a global leader in rapid diagnostic tests, today announced that it has reached a settlement with the United ...